Work

Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab (S33.004)

Year: 2017

Type: article

Source: Neurology

DOI: 10.1212/wnl.88.16_supplement.s33.004

Authors: Michelle Mellion, Keith R. Edwards, Raymond Hupperts, Jelena Drulović, Xavier Montalban, Hans-Peter Hartung, Bruno Brochet, Peter A. Calabresi, Richard Rudick, Adama Ibrahim, Yiwei Zhang, Lei Xu, Diego Cadavid

Institutions: Biogen (United States), Maastricht University, Zuyderland Medisch Centrum, University of Belgrade, Vall d'Hebron Hospital Universitari, Heinrich Heine University Düsseldorf, Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux, Johns Hopkins University, Johns Hopkins Medicine, Fulcrum Therapeutics (United States)

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2786876016

FWCI: 4.299

Cites:

Cited by: 23

Related to: 10